Bayer Aktiengesellschaft

Julius-maximilians-universitat Wurzburg

Bayer Aktiengellschaft

Osteopharma Inc.

Europaisches Laboratorium Molekularbiologie

Walter Sebald

Rudolf H Hanko

Hanno Wild

Hermann Wehlmann

Hartmut Oschkinat

Luis Serrano

Heiner Apeler

Jurgen Beunink

Helena Domingues

Michael Dorschug

David Cregut

Hans-Dietrich Horlein

The present invention is related to a mutein of a bone morphogenetic protein, whereby the mutein comprises an amino acid substitution compared to the wildtype of the bone morphogenetic protein at the amino acid position corresponding to amino acid position 51 of human BMP-2.

Mutein of a bone morphogenetic protein and use thereof

The invention pertains to polypeptide variants with increased heparin-binding ability. Increased heparin-binding ability is achieved by addition, insertion, and/or substitution of an amino acid sequence XXXXXX(SEQ ID NO. 1 or NO.2). Polypeptide variants according to the invention are particularly suited for stimulation of chondrogenesis, osteogenesis, and wound healing. The invention also pertains to amino acid molecules that encode said polypeptide variants, host cells containing said nucleic acid molecules, and processes for producing the polypeptide variants.

Polypeptide variants with increased heparin-binding capacity

The design of antagonists of 4-helix bundle cytokine specific receptors, mimetic peptides that are able to act as such antagonists and their use as pharmaceutical agents is disclosed.

Coiled-coil dimer derived antagonists of 4-helix bundle cytokines, design and uses thereof

hIL-4 mutant proteins used as antagonists or partial agonists of human

Therapeutic agents which are antagonists or partial agonists of human

Growing community of inventors

Würzburg, Germany

Walter Sebald